Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents - Monitor Patents Logo icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

USPTO Class 530  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14: Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
08/28/2014 > 14 patent applications in 9 patent subcategories.

20140243498 - Method for purification of cleaved pro-insulin: The present invention is within the field of biomolecule purification. More closely the invention relates to chromatographic purification of insulin using a specific kind of shell beads having an inner core and an outer functionalized layer. The method enables purification at high flow rates and high purity, over 90%.... Agent:

20140243500 - Calibration and normalization systems and methods for radiopharmaceutical synthesizers: The present invention relates to calibration and normalization systems and methods for ensuring the quality of radiopharmaceuticals during the synthesis thereof, such as radiopharmaceuticals used in Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT).... Agent:

20140243499 - Peptide derivatives and use thereof as carriers for molecules in the form of conjugates: The invention relates to peptide derivatives (peptides and pseudo-peptides) and use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bound to a molecule of interest. The peptides and prodrug conjugates of the invention can be used to vectorise... Agent: Universite D'aix Marseille

20140243501 - Histone deacetylase inhibitors and synthetic method thereof and use thereof in manufacture of medicaments: The invention provides histone deacetylase (HDAC) inhibitors shown as Formula I, where R1 to R8 are as defined in the specification. The invention also provides methods for synthesis of these compounds and applications of these compounds in preparing pharmaceuticals for preventing or treating mammal diseases related to the dysregulation of... Agent: Nanjing Yoko Pharmaceutical Co., Ltd. [cn/cn]

20140243506 - Antagonists of il17c for the treatment of inflammatory disorders: The present invention provides antagonists of IL17C for use in the treatment of an inflammatory disorder.... Agent:

20140243504 - Antibodies comprising chimeric constant domains: Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain Fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric Fc-containing antibodies, antigen-binding proteins and Fc-fusion proteins in cell systems,... Agent: Regeneron Pharmaceuticals, Inc.

20140243502 - Anticoagulation agent and uses thereof: The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe... Agent: Baker Idi Heart And Diabetes Institute Holdings Limited

20140243505 - Bispecific antibody: Provided are bispecific antibodies comprised of a single-chain unit having specificity to an immune cell and a monovalent unit having specificity to a tumor cell or a microorganism. The single-chain unit includes a single-chain variable fragment (scFv) fused to an Fc fragment and the monovalent unit includes a light chain... Agent: Wuhan Yzy Biopharma Co., Ltd.

20140243503 - Fgf21 mutants and uses thereof: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.... Agent: Amgen Inc.

20140243507 - Method of screening antibodies with high antigen selectivity: Provided is a method of screening a target-specific antibody for an antigen that undergoes structural change in a particular physiological condition.... Agent: Samsung Electronics Co., Ltd.

20140243508 - Method for the purification of antibodies: A method for the purification of immunoglobulins by ion exchange chromatography is described. The chromatographic method uses a weak ion exchange resin and a single step elution process for the purification of an immunoglobulin. Additionally a method for the determination of the salt concentration for the single step elution of... Agent: Hoffmann-la Roche Inc.

20140243509 - Near infrared fluorogen and fluorescent activating proteins for in vivo imaging and live-cell biosensing: Tissue slices and whole organisms offer substantial challenges to fluorescence imaging. Autofluorescence and absorption via intrinsic chromophores, such as flavins, melanin, and hemoglobins, confound and degrade output from all fluorescent tags. An “optical window,” farther red than most autofluorescence sources and in a region of low hemoglobin and water absorbance,... Agent:

20140243510 - Methods for purifying erythropoietin analogs having lower isoelectric point: The present invention relates to a method for purifying an erythropoietin analog having a low isoelectric point below 4 by adding an N-linked sugar chain with high purity. In accordance with the present invention, the erythropoietin analog having an isoelectric point below 4, which is an isoform having more sialic... Agent: Chong Kun Dang Pharmaceutical Corp.

20140243511 - Functionalized lignin and method of producing the same: In this study, commercially available softwood lignin was esterified with tall oil fatty acid (TOFA) and tested as barrier material in fiber-based packaging material. The modified lignin samples were applied with a bar coater forming an even coating on the paperboard substrate. A significant decrease in WVTR and OTR value... Agent:

08/21/2014 > 20 patent applications in 15 patent subcategories.

20140235819 - Deuterated cyclosporine analogs and methods of making the same: Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution... Agent: Aurinia Pharmaceuticals, Inc.

20140235820 - Methods and compositions for modulating the wnt pathway: The invention provides methods and compositions for modulating the Wnt signaling pathway, in particular by interfering with binding of Dkk1 or SOST with LRP5 and/or LRP6.... Agent: Genentech, Inc.

20140235821 - Novel phosphatidylinositol-3-kinase inhibitor and pharmaceutical composition: A substance contains a phosphatidylinositol-3-kinase (PI3K) inhibitor including a depsipeptide-class compound represented by formula (1), or a physiologically acceptable salt thereof that combines a PI3K inhibitory effect and an HDAC inhibitory effect to provide an anti-cancer pharmaceutical composition for the treatment of an intractable cancer.... Agent: Tohoku University

20140235822 - Method for producing peptide: The present invention provides a method for producing a peptide, characterized in that it comprises converting an —SH group of a peptide comprising an amino acid residue having the —SH group to an —OH group, wherein said method comprises the following steps (a) to (c): (a) allowing an —SH group... Agent: Glytech, Inc.

20140235823 - Fusion protein containing a single-stranded dna binding protein and methods for expression and purification of the same: The present invention provides an expression vector comprising a promoter and a polynucleotide sequence encoding a fusion protein. The present invention further provides a method for purification of an interest protein. The present invention also provides a fusion protein comprising a single-stranded DNA binding protein and an interest protein or... Agent:

20140235824 - Method to wash greasy wool, a method to separate lanolin from the said greasy wool, wool and lanolin obtainable by these methods: A method to wash wool containing lanolin and impurities includes the steps of providing a volume of an aqueous liquid at a temperature below a melting temperature of the lanolin, soaking the wool in the volume of the liquid, creating air bubbles in the liquid and allowing the air bubbles... Agent:

20140235825 - Biocompatible phase invertible proteinaceous compositions and methods for making and using the same: Biocompatible phase invertible proteinaceous compositions and methods for making and using the same are provided. Phase invertible compositions in accordance with the invention are prepared by combining a liquid proteinaceous substrate and a liquid crosslinking composition, where the liquid crosslinking composition includes a macromolecular crosslinking agent. Also provided are kits... Agent: Tenaxis Medical, Inc.

20140235826 - Optically-based stimulation of target cells and modifications thereto: Stimulation of target cells using light, e.g., in vivo or in vitro, is implemented using a variety of methods and devices. One example involves a vector for delivering a light-activated molecule comprising a nucleic acid sequence that codes for light-activated molecule. The light-activated molecule includes a modification to a location... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20140235830 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent: Amgen, Inc.

20140235829 - Compositions and methods for regulation of tumor necrosis factor-alpha: The present invention relates to compositions and methods relating to an interleukin 18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression.... Agent:

20140235828 - Gram-positive bacteria specific binding compounds: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.... Agent: Genentech, Inc.

20140235827 - Mouse anti-aggrus monoclonal antibodies: The present invention provides a monoclonal antibody or a functional fragment thereof, capable of recognizing Aggrus epitope comprising an amino-acid sequence represented by a sequence ID 1, 3, or 4, and the monoclonal antibody or the functional fragment thereof produced from a hybridoma with deposit ID of FERM BP-11446, FERM... Agent: Japanese Foundation For Cancer Research

20140235831 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent: Amgen, Inc.

20140235832 - Rank ligand polypeptides: Described herein are kits for use in detecting RANKL polypeptides.... Agent: Immunex Corporation

20140235833 - Method of classifying antibody, method of identifying antigen, method of obtaining antibody or antibody set, method of constructing antibody panel and antibody or antibody set and use of the same: The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors... Agent: Fujita Health University

20140235834 - Method for preparing polybiotinylated compounds: The present invention relates to compounds having the formula (I) and their use in clinical and industrial diagnosis.... Agent: Biom&#xe9 Rieux

20140235835 - Calicheamicin derivative-carrier conjugates: Methods for preparing monomeric cytotoxic drug/carrier conjugates with a drug loading significantly higher than in previously reported procedures and with decreased aggregation and low conjugate fraction (LCF) are described. Cytotoxic drug derivative/antibody conjugates, compositions comprising the conjugates and uses of the conjugates are also described. Monomeric calicheamicin derivative/anti-CD22 antibody conjugates,... Agent: Wyeth Holdings LLC

20140235836 - Immunologic constructs and methods: The present invention relates to improved vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine and/or reduce reactogenicity to the vaccine when administered. In particular the vaccines and immunogenic compositions of the present invention relate to flagellin-antigen fusion proteins in which the spatial orientation... Agent: Vaxinnate Corporation

20140235837 - Method for purifying protein: The present invention provides a method for purifying a protein, comprising an adsorption step and an elution step, wherein in the elution step, at least one eluent is passed in the opposite direction with respect to the direction of the passage of a stock solution containing an adsorption target protein,... Agent: Asahi Kasei Chemicals Corporation

20140235838 - Selective aerobic alcohol oxidation method for conversion of lignin into simple aromatic compounds: Described is a method to oxidize lignin or lignin sub-units. The method includes oxidation of secondary benzylic alcohol in the lignin or lignin sub-unit to a corresponding ketone in the presence of unprotected primarily aliphatic alcohol in the lignin or lignin sub-unit. The optimal catalyst system consists of HNO3 in... Agent: Wisconsin Alumni Research Foundation

08/14/2014 > 12 patent applications in 11 patent subcategories.

20140228539 - Separation of acetylated proteins from unacetylated proteins: The invention relates to a process for separating acetylated proteins from unacetylated proteins. In particular, the invention relates to a process of using multimodal chromatography to separate acetylated proteins from unacetylated proteins. In the prior art, multimodal chromatography is used to isolate antibodies. The invention found that multimodal chromatography can... Agent: La Jolla Biologics, Inc.

20140228540 - Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods: The present invention relates to TIMP-3 binding compositions, methods of producing such compositions, and methods of using such compositions, including in the treatment of various conditions.... Agent: Amgen Inc.

20140228541 - Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules: The present application discloses compositions and methods of synthesis and use of 18F- or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex... Agent: Immunomedics, Inc.

20140228542 - Method for producing peptide fractions and use thereof: The invention relates to a method for producing enriched peptide fractions from protein-containing raw materials, in which protein hydrolysates are separated using chromatography, according to the physiochemical properties thereof, by means of stationary phases with an aqueous solution as an elution agent.... Agent:

20140228543 - Modified and derivatized ß-glucan compounds, compositions, and methods: Modified and/or derivativized β-glucans with an enhanced capacity to modulate human immune response as compared to the parent, unmodified and/or underivatized β-glucans are demonstrated.... Agent:

20140228545 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent: Amgen, Inc.

20140228544 - Constructs and libraries comprising antibody surrogate light chain sequences: The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same.... Agent: Sea Lane Biotechnologies LLC

20140228546 - Serum albumin binding proteins: The present invention relates to amino acid sequences that are capable of binding to serum albumin; to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise... Agent: Ablynx N.v.

20140228547 - Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9): Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen... Agent: Amgen, Inc.

20140228548 - Viral clearance methods: The invention provides methods for separating a polypeptide of interest (such as an antibody) from a virus. In some embodiments, the methods involve eluting the polypeptide of interest from a Protein A resin with an elution buffer have a particular range of conductivity values that minimizes the amount of virus... Agent: Human Genome Sciences

20140228549 - Process for separation/purification of biomolecules: A method to at least one of separate and purify biomolecules via an aqueous two-phase extraction includes providing the biomolecules in a first aqueous phase, providing a porous material comprising pores, providing a second aqueous phase at least in the pores of the porous material, and, at least one of... Agent: Technische Universitaet Dortmund

20140228550 - Process for obtaining proteins from a native substance mixture: A process is provided for obtaining proteins from native substance mixtures, wherein a native substance mixture is first finely disintegrated and optionally processed to form a flowable slurry (I) by adding liquid. The process includes the following steps: (i) setting the pH value of the slurry (I) in an alkaline... Agent: Gea Mechanical Equipment Gmbh

08/07/2014 > 25 patent applications in 18 patent subcategories.

20140221606 - Aspart proinsulin compositions and methods of producing aspart insulin analogs: Aspart modified proinsulin sequences that have a modified C-peptide amino acid and/or nucleic acid modification for producing aspart insulin analogs are provided. Highly efficient processes for preparing the aspart insulin analogs and improved preparations containing the aspart insulin analogs prepared according to the methods described herein are also provided.... Agent: Elona Biotechnologies Inc.

20140221608 - Acid-cleavable linkers exhibiting altered rates of acid hydrolysis: An acid-cleavable peptide linker comprising aspartic acid and proline residues is disclosed. The acid-cleavable peptide linker provides an altered sensitivity to acid-hydrolytic release of peptides of interest from fusion peptides of the formula PEP1-L-PEP2. The inventive linker, L, is described in various embodiments, each of which provides substantially more rapid... Agent: E I Du Pont De Nemours And Company

20140221607 - Monoclonal antibody and antigens for diagnosing and treating lung disease and injury: The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure... Agent: Indiana University Research And Technology Corp.

20140221609 - Activation of sodium potassium atpase: Activation sites on the alpha subunit of sodium potassium ATPase have been discovered. It has also been discovered that certain antibodies that bind to the alpha subunit of sodium potassium ATPase dramatically increase enzyme activity. There has never before been a report of precise activation sites or drug interaction sites... Agent:

20140221610 - Dispersion and detachment of cell aggregates: Compositions comprising a protein or isolated peptide, and methods using the same for preventing, dispersing or detaching a biofilm, are disclosed.... Agent: Hutchison Biofilm Medical Solutions Ltd.

20140221611 - Binding molecules for human factor viii and factor viii-like proteins: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of... Agent: Dyax Corp.

20140221612 - Peptides that selectively home to heart vasculature and related conjugates and methods: The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below.... Agent: Sanford-burnham Medical Research Institute

20140221613 - Novel modified protein comprising tandem-type multimer of mutant extracellular domain of protein g: The purpose of the present invention is: to provide an excellent protein which is further reduced in the binding property to an Fc region of an immunoglobulin and/or the binding property to an Fab region of the immunoglobulin in a weakly acidic region compared with that of a protein containing... Agent:

20140221614 - Collagen matrix with locally controlled intrafibrillar and extrafibrillar mineral content and methods of producing: A mineralized collagen matrix with an intrafibrillar and/or extrafibrillar gradient of mineralization for insertion replacement is disclosed. The intrafibrillar mineralization of the collagen matrix is formed by the addition of fetuin to the simulated body fluid. The gradient of intrafibrillar mineralization may stiffen the collagen matrix and simulate a natural... Agent: The Washington University

20140221615 - Porous scaffold material, and method for producing same: Provided are a scaffold material that functions as a scaffold material for two weeks or more in vivo and causes substantially no foreign-body reaction, and a method for producing the scaffold material. Specifically, a porous scaffold material comprising collagen fibers is provided.... Agent: Kyoto University

20140221616 - Haptens of quetiapine: The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from quetiapine. The invention also relates to conjugates of a quetiapine hapten and a protein.... Agent: Janssen Pharmaceutica Nv

20140221617 - Canola protein product with low phytic acid content (\"c702\"): Canola protein products having a protein content of at least about 60 wt % (N×6.25) d.b., preferably at least about 90 wt %, more preferably at lease about 100 wt %, and low phytic acid content, are produced by extracting canola seeds or canola oil seed meal with an aqueous... Agent:

20140221618 - Targeted coagulation factors and method of using the same: Targeted coagulation factors comprising a coagulation factor linked with at least one domain that specifically binds to a membrane protein on a blood cell is provided. The disclosed targeted coagulation factors increase the efficiency of coagulation factors and prolong their duration of action and thus, are an improvement for the... Agent:

20140221619 - Methods and compositions for increasing protein production: The disclosure provides methods and materials for increasing the expression of a protein of interest such as an antibody by a cell. ABC50 expression or activity is increased which increases expression of the protein or antibody of interest. The disclosure also provides methods and materials for increasing the sensitivity of... Agent: University Health Network

20140221620 - Anti-human p-cadherin (cdh3) recombinant antibody: It is an object to provide a recombinant antibody that is an anti-CDH3 antibody having cytotoxicity on CDH3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention... Agent: Perseus Proteomics Inc.

20140221624 - Humanization of rabbit antibodies using a universal antibody framework: The present invention relates to an universal antibody acceptor framework and to methods for grafting non-human antibodies, e.g., rabbit antibodies, using a universal antibody acceptor framework. Antibodies generated by the methods of the invention are useful in a variety of diagnostic and therapeutic applications.... Agent: Esbatech - A Novartis Company LLC

20140221623 - Interleukin-6 receptor binding polypeptides: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as... Agent: Ablynx N.v.

20140221622 - Monovalent binding proteins: Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.... Agent: Abbvie, Inc.

20140221621 - Single-chain multivalent binding protein compositions and methods: Provided are protein, nucleic acid, and cellular libraries of single chain multivalent binding proteins (e.g., scDVD and scDVDFab molecules) and methods of using these of these libraries for the screening of single chain multivalent binding proteins using cell surface display technology (e.g., yeast display).... Agent: Abbvie, Inc.

20140221625 - B cell lineage based immunogen design with humanized animals: Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are... Agent:

20140221626 - Compositions and methods for detection of methadone metabolite: Methods and reagents are disclosed for conducting assays for EDDP. The reagents include a moiety selected from the group consisting of poly(amino acid) label moieties, non-poly(amino acid) label moieties, poly(amino acid) immunogenic carriers, non-poly(amino acid) immunogenic carriers, non-label poly(amino acid) moieties, and non-immunogenic carrier poly(amino acid) moieties linked to 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine... Agent: Siemens Healthcare Diagnostics Inc.

20140221627 - Methods for preparation of fucose-linked site specific conjugates of proteins with toxins, adjuvants, detection labels and pharmacokinetic half life extenders: The present invention relates to eukaryotic cells for producing molecules having an atypical fucose analogue on their glycomoieties and/or amino acids. It also relates to methods for producing molecules having an atypical fucose analogue on their glycomoieties and/or amino acids and to molecules obtainable by said methods. It further relates... Agent: Probiogen Ag

20140221628 - Influenza virus-like particles comprising adjuvant-fused m2 protein to enhance the immunogenicity of vaccine: A DNA vaccine comprising hyperglycosylated mutant HA gene, which is derived from avian influenza virus, is provided. A DNA vaccine composition comprising: (a) the DNA vaccine; and (b) a booster is also provided. An influenza virus-like particle comprising adjuvant-fused M2 protein is further provided. A method for eliciting an immune... Agent: National Tsing Hua University

20140221629 - Ultrafiltration membranes and methods of making: The present invention is an integral multilayered composite membrane having at least one ultrafiltration layer made by cocasting or sequentially casting a plurality of polymer solutions onto a support to form a multilayered liquid sheet and immersing the sheet into a liquid coagulation bath to effect phase separation and form... Agent: Emd Millipore Corporation

20140221630 - Method and system for processing of aquatic species: Disclosed herein is a method and system of recovering multiple products from industrial-scale production of a biomass of an aquatic species.... Agent: Pa LLC

Previous industry: Synthetic resins or natural rubbers -- part of the class 520 series
Next industry: Organic compounds -- part of the class -570 series


RSS FEED for 20140828: xml
Integrate into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.


Thank you for viewing Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents on the website. These are patent applications which have been filed in the United States. There are a variety ways to browse Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof patents we recommend signing up for free keyword monitoring by email.

Results in 0.74018 seconds